Bosh sahifaEYPT • NASDAQ
add
Eyepoint Pharmaceuticals Inc
8,95 $
Seans yopilganidan keyin:(1,45%)+0,13
9,08 $
Yopilgan:22-noy, 18:19:48 (GMT-5) · USD · NASDAQ · Ogohlantirish
Yopilish kursi
8,35 $
Kunlik diapazon
8,20 $ - 9,32 $
Yillik diapazon
5,87 $ - 30,99 $
Bozor kapitalizatsiyasi
609,46 mln USD
Oʻrtacha hajm
1,10 mln
Narx/foyda
-
Dividend daromadliligi
-
Asosiy maydon
NASDAQ
Yangiliklarda
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (USD) | sen, 2024info | Y/Y qiyosi |
|---|---|---|
Daromad | 10,52 mln | -30,77% |
Joriy xarajat | 13,96 mln | 23,25% |
Sof foyda | -29,36 mln | -132,80% |
Sof foyda marjasi | -278,99 | -236,29% |
Har bir ulushga tushum | -0,54 | -63,64% |
EBITDA | -32,34 mln | -126,42% |
Amaldagi soliq stavkasi | — | — |
Balans
Jami aktivlari
Jami passivlari
| (USD) | sen, 2024info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 253,79 mln | 86,60% |
Jami aktivlari | 300,92 mln | 88,02% |
Jami passivlari | 82,18 mln | -18,97% |
Umumiy kapital | 218,73 mln | — |
Tarqatilgan aksiyalar | 68,25 mln | — |
Narxi/balansdagi bahosi | 2,04 | — |
Aktivlardan daromad | -26,19% | — |
Kapitaldan daromad | -33,18% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (USD) | sen, 2024info | Y/Y qiyosi |
|---|---|---|
Sof foyda | -29,36 mln | -132,80% |
Operatsiyalardan naqd pul | -39,03 mln | -156,70% |
Sarmoyadan naqd pul | 16,20 mln | 1 041,63% |
Moliyadan naqd pul | 11,89 mln | 14,78% |
Naqd pulning sof oʻzgarishi | -10,94 mln | -66,70% |
Boʻsh pul | -27,63 mln | -1 572,56% |
Haqida
EyePoint Pharmaceuticals, Inc. pSivida is a Watertown, Massachusetts company specialising in the application of microelectromechanical systems and nanotechnology to drug delivery.
pSivida obtained porous silicon technology from the British government Defence Evaluation and Research Agency. QinetiQ continues to be a strategic partner.
In June 2004, pSivida acquired full ownership of pSiMedica. In April 2018, pSivida purchased eye products firm Icon Bioscience. Wikipedia
Tashkil etilgan
1987
Xodimlar soni
121
